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Abstract
Biguanides have been developed for the treatment of
hyperglycemia and type 2 diabetes. Recently,
metformin, the most widely prescribed biguanide, has
emerged as a potential anticancer agent.
Epidemiological, preclinical and clinical evidence
supports the use of metformin as a cancer
therapeutic. The ability of metformin to lower
circulating insulin may be particularly important for
the treatment of cancers known to be associated with
hyperinsulinemia, such as those of the breast and
colon. Moreover, metformin may exhibit direct
inhibitory effects on cancer cells by inhibiting
mammalian target of rapamycin (mTOR) signaling and
protein synthesis. The evidence supporting a role for
metformin in cancer therapy and its potential
molecular mechanisms of action are discussed.
A brief history of biguanides
The biguanides metformin, phenformin and buformin
are derived from the herb Galega officinalis (French
lilac, also known as Goat’s Rue or Italian Fitch) and
were originally developed for the treatment of hypergly-
cemia and type 2 diabetes. Use of tea infused with
French lilac for relief of frequent urination (polyuria)
and halitosis (a sweet odor on breath), both now well
known symptoms of diabetes, dates back to ancient
Egypt and medieval Europe [1-3]. Work in the 1920 s
identified biguanides as the active compounds from the
French lilac and led to their development as therapeu-
tics in the 1950 s [1,3,4]. While phenformin and bufor-
min were withdrawn from the market in the 1970 s due
to toxicity related to lactic acidosis, metformin (N’,N’-
dimethylbiguanide) remains one of the most commonly
prescribed drugs, with nearly 120 million prescriptions
filled yearly worldwide [5]. Metformin was approved for
the treatment of hyperglycemia in Britain in 1958,
Canada in 1972, and the US in 1995. In addition to its
use in diabetics, metformin is also effective in the treat-
ment of polycystic ovary syndrome and is being
explored as an antiviral and anticancer agent [5-7].
Indeed, the use of biguanides in oncology was originally
initiated in a series of studies targeting altered metabo-
lism in non-diabetic cancer patients [8-10]. More
recently, metformin has been associated with decreased
cancer incidence and mortality in diabetic patients and
the insulin-lowering effects of metformin may be inte-
gral to its anticancer properties [5,11-13]. Here, we dis-
cuss the use of metformin in oncology and its potential
mechanisms of action in the inhibition of cancer.
Discussion
Mechanism of metformin action
At the cellular level, metformin activates AMP-activated
protein kinase (AMPK), an energy sensor involved in
regulating cellular metabolism that is activated by
increases in the intracellular levels of AMP [14,15]. Met-
formin indirectly activates AMPK by disrupting complex
I of the mitochondrial respiratory chain, which leads to
decreased ATP synthesis and a rise in the cellular AMP:
ATP ratio [16]. Increased association of AMPK with
AMP under such conditions leads to stimulation of
AMPK activity by three mechanisms. AMP allosterically
activates AMPK and facilitates phosphorylation of its
catalytic subunit on residue Thr172 by the upstream
kinase liver kinase B1 (LKB1, also known as STK11), the
protein product of the tumor suppressor gene mutated
in the Peutz-Jeghers cancer predisposition syndrome
[17]. Binding of AMP to AMPK also prevents depho-
sphorylation of AMPK Thr172 by protein phosphatases.
Activated AMPK phosphorylates a number of down-
stream targets leading to stimulation of catabolic pro-
cesses that generate ATP, such as fatty acid b-oxidation
and glycolysis, and suppression of many of the processes
dependent on ample cellular ATP supply, including
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gluconeogenesis, protein and fatty acid synthesis and
cholesterol biosynthesis [18,19].
The mechanism of metformin action in the treatment
of diabetes involves the inhibition of hepatic gluconeo-
genesis and the stimulation of glucose uptake in muscle
[20,21]. These effects are achieved by AMPK-mediated
transcriptional regulation of genes involved in gluconeo-
genesis in the liver and those encoding glucose
transporters in the muscle, such as peroxisome prolif-
erator-activated receptor-g coactivator 1a (PGC-1a) and
glucose transporter type 4 (GLUT4), respectively
[5,22,23]. Consequently, metformin enhances insulin
sensitivity and lowers fasting blood glucose and insulin
in diabetics.
Metformin and cancer
The potential for application of metformin in oncology
was first recognized in retrospective epidemiological stu-
dies of diabetic patients with cancer. Numerous observa-
tional studies reported decreased cancer incidence and
cancer-related mortality in diabetics receiving standard
doses of metformin (1500 to 2250 mg/day in adults)
[11,24-28]. For example, Evans and colleagues [11]
reported a reduced risk of subsequent cancer diagnosis in
diabetics receiving metformin (vs those patients not
receiving the drug), with the protective effect increasing
with greater metformin exposure. Additional studies
examining all forms of cancer have reported reduced
cancer risk in diabetics on metformin (vs no metformin
treatment [24,27]) and lower cancer-related mortality in
patients receiving metformin compared to those receiving
other standard diabetic therapies [28]. Furthermore, a
recent epidemiological study of 2,529 women with breast
cancer reported higher pathologic complete response rates
(pCRs; considered a surrogate for overall survival in this
setting) to neoadjuvant systemic therapy in diabetic
patients receiving metformin (pCR 24%) compared to dia-
betic patients not receiving metformin (pCR 8%) and non-
diabetic patients not receiving metformin (pCR 16%)[29].
However, despite the increase in pCR, metformin did not
significantly improve the estimated 3-year relapse-free sur-
vival rate in this study. Moreover, in a similar study of dia-
betic prostate cancer patients, metformin use was not
associated with benefit [30]. Thus, further clinical research
is needed to fully appreciate the impact of metformin on
cancer recurrence and survival.
While the majority of evidence supporting a role for
metformin in the treatment of cancer has been derived
from retrospective studies involving diabetics, some
prospective clinical trials have been completed in non-
diabetic patients. In a recent study, low doses of metfor-
min (250 mg/day) reduced the number of rectal aberrant
crypt foci (a surrogate marker for colorectal cancer) and
decreased the proliferative activity of colonic epithelium
in non-diabetic patients [31]. Furthermore, interim ana-
lyses of ongoing studies involving neoadjuvant metformin
treatment of newly diagnosed breast cancer patients have
demonstrated that metformin is safe and well tolerated,
and exhibits favorable effects on insulin metabolism and
tumor cell proliferation and apoptosis [32,33].
Metformin also displays significant growth inhibitory
effects in several cancer cell and mouse tumor models.
In cell culture, metformin inhibits the proliferation of a
range of cancer cells including breast, prostate, colon,
endometrial, ovarian, and glioma [34-40]. The effects of
metformin on cancer cell proliferation were associated
with AMPK activation, reduced mammalian target of
rapamycin (mTOR) signaling and protein synthesis, as
well as a variety of other responses including decreased
epidermal growth factor receptor (EGFR), Src, and mito-
gen-activated protein kinase (MAPK) activation,
decreased expression of cyclins, and increased expres-
sion of p27. While not universally observed in all cells,
metformin has been found to induce apoptosis in cer-
tain cell lines derived from endometrial cancers, glioma,
and triple negative breast tumors [38,39,41].
Recent studies have demonstrated that metformin may
also target cancer-initiating cells. For example, metformin
inhibited the growth of a subpopulation of breast cancer
cells shown to have such property in culture and reduced
their ability to form tumors in mice [42] and when com-
bined with trastuzumab, metformin reduced the cancer-
initiating cell population in Her2-amplified breast cancer
cells [43]. Interestingly, metformin may also be involved in
regulating breast cancer-initiating cell ontogeny by tran-
scriptionally repressing the process of epithelial to
mesenchymal transition (EMT) [44]. Metformin also
reduced the growth of a variety of tumor xenografts in
mice including those established from breast and prostate
cancer cells [36,41], and suppressed the development of
breast, colon and other tumors in transgenic mice [45,46].
In addition, metformin inhibited the development of che-
mically induced lung tumors and preneoplastic colonic
lesions in mice [47,48].
Mechanism of action in cancer
The anticancer effects of metformin are associated with
both direct (insulin- independent) and indirect (insulin-
dependent) actions of the drug (Figure 1). The indirect,
insulin-dependent effects of metformin are mediated by
the ability of AMPK to inhibit the transcription of key
gluconeogenesis genes in the liver and stimulate glucose
uptake in muscle, thus reducing fasting blood glucose
and insulin [1,20]. The insulin-lowering effects of met-
formin may play a major role in its anticancer activity
since insulin has mitogenic and prosurvival effects and
tumor cells often express high levels of the insulin
receptor, indicating a potential sensitivity to the growth
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Figure 1 Direct and indirect effects of metformin on cancer. Metformin activates AMPK leading to stabilization of TSC2 and inhibition of
mTORC1 signaling and protein synthesis. Metformin can also directly target mTOR independently of AMPK and TSC2. Systemically, metformin
sensitizes tissues to insulin, reduces hepatic gluconeogenesis, and lowers circulating insulin levels, indirectly reducing receptor tyrosine kinase
activation and PI3K signaling. AMPK = AMP-activated protein kinase; 4E-BP1 = eukaryotic initiation factor 4E-binding protein-1; LKB1 = liver kinase
B1; mTORC1 = mammalian target of rapamycin complex 1; PI3K = phosphatidylinositol-3-kinase; PKB/Akt = protein kinase B; PTEN = phosphatase
and tensin homologue deleted on chromosome 10; Rheb = Ras homologue enriched in brain; S6K = ribosomal protein S6 kinase; TSC2 =
tuberous sclerosis complex 2.
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promoting effects of the hormone [49-51]. Further, obe-
sity and high insulin levels are adverse prognostic fac-
tors for a number of cancers particularly those of the
breast, prostate and colon [25,50,52-54]. Consequently,
metformin may diminish the negative effects of insulin
on tumor development and growth. Indeed, metformin
suppressed the stimulatory effects of obesity and hyper-
insulinemia on lung tumor growth in mice by improving
insulin sensitivity, lowering circulating insulin, and acti-
vating AMPK signaling [13]. In addition, metformin
reduced circulating insulin levels by 22% and improved
insulin sensitivity by 25% in non-diabetic women with
breast cancer, highlighting the insulin-lowering effects of
metformin as a potential mechanism of action in the
treatment of breast cancer [12].
The direct, insulin-independent effects of metformin
originate from LKB1-mediated activation of AMPK and
a reduction in mTOR signaling and protein synthesis in
cancer cells [34] (Figure 1). AMPK impacts mTOR via
phosphorylation and activation of the tumor suppressor
tuberous sclerosis complex 2 (TSC2, tuberin), which
negatively regulates mTOR activity [55]. mTOR is a key
integrator of growth factor and nutrient signals and is a
critical mediator of the phosphatidylinositol-3-kinase/
protein kinase B/Akt (PI3K/PKB/Akt) signaling pathway,
which is one of the most frequently deregulated molecu-
lar networks in human cancer [56,57]. Metformin-
mediated AMPK activation leads to an inhibition of
mTOR signaling, a reduction in phosphorylation of its
major downstream effectors, the eukaryotic initiation
factor 4E-binding proteins (4E-BPs) and ribosomal pro-
tein S6 kinases (S6Ks), and an inhibition of global pro-
tein synthesis and proliferation in a number of different
cancer cell lines [34,35,40,58].
Some recent reports raise the possibility that metfor-
min may mediate additional anticancer effects indepen-
dently of AMPK, LKB1, and TSC2 [59,60]. Indeed,
metformin reduced mTOR signaling independently of
AMPK and TSC2 by inhibiting Rag GTPase-mediated
activation of mTOR [59]. Paradoxically, at least in one
cell model system, loss of function of LKB1 sensitized
cells to the inhibitory effects of metformin under condi-
tions of low glucose [61]. Moreover, metformin reduced
hepatic gluconeogenesis by lowering hepatic energy
levels in the absence of AMPK and LKB1 [60]. While
these additional effects are intriguing, LKB1-dependent
suppression of mTOR signaling remains the key candi-
date mechanism of antitumor action of metformin.
Conclusions and future work with metformin in
cancer
The clinical safety, well characterized pharmacodynamic
profile, and low cost of metformin make it an ideal candi-
date for development as an anticancer agent. The recent
convergence of epidemiologic, clinical and preclinical evi-
dence supporting a potential anticancer effect of metfor-
min has led to an explosion of interest in evaluating this
agent in human cancer. However, a number of issues
need further consideration in the development of metfor-
min as a cancer therapy. In particular, the retrospective
epidemiological studies that first identified the potential
anticancer effects of metformin are difficult to confirm
and contain only diabetic patient populations. While cell
culture and mouse models have been integral to the char-
acterization of the mechanism of action of metformin in
the inhibition of cancer, they are artificial and rely on
non-physiological doses of metformin in the presence of
excess insulin and growth factors. New, more physiologi-
cally relevant in vitro models will be required to fully elu-
cidate the mechanism of action of metformin (both the
insulin-dependent and insulin-independent actions) and
inform clinical studies. Furthermore, additional research is
required to identify key patient and tumor factors that
govern metformin sensitivity, which is critical for the
design of clinical trials and the identification of patients
best suited for metformin treatment. Current preclinical
and clinical knowledge of metformin action suggest that
patients exhibiting hyperinsulinemia and tumors expres-
sing the insulin receptor, LKB1, and TSC2 would benefit
most from metformin therapy, while patients with normal
circulating insulin levels and tumors lacking expression of
the insulin receptor, LKB1, and TSC2 would likely be
unresponsive to the drug. Predicting how non-diabetic
patients will respond to metformin and differentiating
between its direct and indirect effects may be challenging.
However, the initiation of new, focused clinical trials con-
taining strong correlative science components will be cru-
cial in understanding the effects of the drug on a range of
cancer patients (including non-diabetic patients) and the
identification of biomarkers that predict metformin bene-
fit and response to therapy. Currently, a number of clini-
cal trials examining the use of metformin as a cancer
therapy are underway including studies in prostate, breast,
endometrial and pancreatic cancer patients. In fact, the
National Cancer Institute of Canada Clinical Trials Group
(NCIC CTG) has initiated a large phase III clinical trial
(NCIC CTG MA.32) examining the effect of metformin
versus placebo in over 3,500 women with early stage
breast cancer [62]. Coupled with the implementation of
new preclinical models, these clinical trials will be integral
to the development and effective use of metformin as a
potential anticancer therapy.
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